The American Academy of Pediatrics (AAP) has released new guidance for pediatricians regarding the use of fecal microbiota transplantation (FMT) in children. This guidance is detailed in a clinical report titled “Guidance for the Clinician in Rendering Patient Care Fecal Microbiota Transplantation: Information for the Pediatrician,” published in the December 2023 issue of Pediatrics. Key points from the AAP’s guidance include: The AAP’s clinical report supports the joint society statement by the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology and Nutrition.
Author: Abhay Panchal
The American Gastroenterological Association (AGA) has released a new guideline, published in Gastroenterology, recommending the use of blood and stool-based biomarkers for managing Crohn’s disease. This guideline marks a significant advancement in the non-invasive monitoring of this condition. Key points from the guideline include: The guideline underscores that biomarkers are no longer experimental and should be an integral part of IBD care. They offer a less invasive, more cost-effective alternative to frequent colonoscopies and allow for more frequent assessments for tighter disease control and better long-term outcomes in Crohn’s disease patients.
UnitedHealthcare (UHC) is facing a class action lawsuit for allegedly using an artificial intelligence (AI) system, nH Predict, to deny patient claims in Medicare Advantage plans. The lawsuit, filed in Minnesota district court, claims UHC used this technology to systematically reject skilled nursing facility (SNF) claims, contradicting Medicare’s coverage standards and doctor recommendations. The AI model, acquired by UHC’s parent company in 2020, is accused of having a 90% error rate, leading to significant out-of-pocket expenses for patients. The lawsuit highlights two cases: Gene Lokken, who incurred about $150,000 in expenses, and Dale Tetzloff, who paid around $70,000. Both patients…
A study published in JAMA Network Open, finds that conventional colonoscopy remains the most cost-effective method for universal colorectal cancer (CRC) screening in average-risk adults in the US, compared to circulating tumor DNA-based methods (liquid biopsy). Key points from the study include: The study underscores the current economic advantage of colonoscopy for CRC screening while acknowledging the potential future role of liquid biopsy as technology advances.
Universal DX (UDX), a liquid biopsy firm, successfully closes a Series B financing round of approximately $70 million. Key highlights from the article include: The article underscores the significant progress in developing non-invasive, efficient methods for colorectal cancer screening, which could potentially transform cancer detection and management.
Researchers at UMass Lowell’s Zuckerberg College of Health Sciences are investigating the connection between the gut microbiome and the risk of Parkinson’s and Alzheimer’s diseases. This research could lead to earlier detection and novel treatments for these neurodegenerative diseases, which affect millions globally. Key findings and initiatives from the study include: Link Between Gut Microbiome and Parkinson’s Disease: The study, led by Associate Professor Natalia Palacios, found that healthy, anti-inflammatory bacteria were less abundant in individuals diagnosed with Parkinson’s disease. This suggests a potential link between gut inflammation and Parkinson’s, with changes in the gut microbiome observable before the disease’s…
Claris GenomiX, a precision oncology company, has announced the licensing availability of ColoType, its patented mRNA-based Consensus Molecular Subtyping (CMS) assay. This diagnostic tool is designed to guide treatment decisions for colorectal cancer (CRC). Key highlights from the announcement include:
Biotech company AnchorDx has formed a long-term partnership with molecular diagnostics firm DiaCarta to develop and commercialize cancer diagnostic products globally. Based in Guangzhou, China, AnchorDx, and Pleasanton, California-based DiaCarta plan to leverage their proprietary technologies for DNA methylation and mutation detection in this collaboration. The financial and other terms of the partnership were not disclosed. AnchorDx aims to accelerate its early cancer screening programs and develop a robust product pipeline through this collaboration. The company’s pipeline currently covers over 70% of high-incidence cancers. AnchorDx received breakthrough device designation from the U.S. Food and Drug Administration in 2021 for its…
The Managed Healthcare Executive article discusses the promising role of drone technology in healthcare delivery, particularly in addressing challenges like poor road conditions, transportation limitations, and the need for efficient responses to healthcare emergencies. The study featured in the online PLOS Journal highlights the favorable reception of drone technology for delivering healthcare goods and supplies, especially when environmental factors are mitigated. Key points from the article include:
The CancerX initiative, part of the White House-led Cancer Moonshot program, is making significant strides in advancing cancer care through digital innovation. Jennifer Goldsack, CEO of the Digital Medicine Society (DiMe), which co-hosts CancerX, discussed the current state and future directions of the initiative in an interview with MobiHealthNews. Key points include: Progress and Plans: In its second year, CancerX, under the co-hosting of DiMe and Moffitt Cancer Center, has announced its inaugural members and is preparing to release resources focused on using digital technologies to address financial toxicity and equity in cancer care and research. Data Sprint and Payment…